SE Michigan heavily represented at Future Leaders in Biotech Industry event.
Ann Arbor-based companies will have a big presence at the 22nd annual Future Leaders in the Biotech Industry conference in New York City on March 20.
Sixty early-stage companies will make presentations —four of them are based in Ann Arbor, three of them spinoffs from the University of Michigan.
The most established of them is Esperion Therapeutics Inc., a company that has a drug in human trials to lower cholesterol in patients who are intolerant of the statin class of drugs normally used to treat metabolic disorders.
Esperion had an initial public offering in June 2013 of $70 million.
The three UM spinoffs are ONL Therapeutics, Atterocor Inc. and Lycera Corp.
ONL Therapeutics was launched last year with $2 million in grants to help patients with a range of retinal conditions improve their vision by protecting photorecepters in the eye.
In 2013, Lycera announced it had entered into a second agreement with Merck & Co. Inc., the New Jersey-based drug giant, that could provided more than $300 million to develop small-molecule drugs to treat a range of immune-response-related disorders. Here's more about that agreement.
Atterocor got $16 million in venture capital in 2012 to fund trials of a drug to treat adrenal cancer, a rare but lethal form of cancer. The company was founded by Raili Kerppola, who had been diagnosed with the disease and died at age 51 before she could hit her goal of seeing it being administered to patients in human trials. Read more about those trials here.